3 Sorafenib (Nexavar ) A Novel, Orally-Active Multi-Kinase Inhibitor Approved in the US in Dec 2005 for advanced RCC In vitro inhibitor of C-Raf, wild-type B-Raf, b-raf V600E, VEGFR -1/-2/-3, PDGFR-β, c- Kit, and Flt-3 1 Broad-spectrum anti-tumour activity and inhibition of angiogenesis in several tumour xenografts 1 Sorafenib prevented tumour growth in RCC VHL / xenografts, via inhibition of angiogenesis 2 1. Wilhelm S, Chien DS. Curr Pharm Des 2002;8: Chang YS, et al. Clin Cancer Res 2005;11:9011S
4 Sorafenib: phase II and III studies Based on phase I data, continuous oral dosing of sorafenib 400mg twice daily (b.i.d.) was selected for further evaluation in patients with advanced RCC Sorafenib phase II and III clinical trials: phase II Randomised Discontinuation Trial (RDT) phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGETs) randomised phase II trial of sorafenib versus IFN (first-line) phase II trial in Japanese patients
5 Phase II RDT: study design Response assessment (change from baseline in bidimensional tumour measurements) Tumour shrinkage 25% Sorafenib 400mg b.i.d. open-label Sorafenib 400mg b.i.d. 12-week run-in Tumour growth/ shrinkage <25% Sorafenib 400mg b.i.d. 12 weeks Placebo * 12 weeks Progression-free at 24 weeks (%) Tumour growth 25% Off study * Patients who progressed on placebo could cross over to sorafenib
6 Phase II RDT: sorafenib significantly delayed progression compared with placebo At 24 weeks, 50% of patients with advanced RCC remained progression free in the sorafenib group compared with 18% in the placebo group (p=0.0077) 100 Placebo (n=33) Sorafenib (n=32) Censored observation 75 Median PFS from PFS (% patients) randomisation: Placebo = 6 weeks Sorafenib = 24 weeks p= week Time from randomisation (weeks) run-in period Ratain MJ, et al. J Clin Oncol 2006;24:
7 SORAFENIB improves PFS over placebo in 2nd line setting Eligibility criteria Histologically/cytologically confirmed, unresectable and/or metastatic disease Clear-cell histology Measurable disease Failed one prior systemic therapy in last 8 months ECOG PS 0 or 1 Good organ function No brain metastasis Poor risk Motzer group excluded (1:1) Randomization n~905 Stratification Motzer criteria Country Sorafenib 400 mg bid Placebo Major endpoints Survival (alpha=0.04) PFS (alpha=0.01) Escudier et al, NEJM 2007
8 TARGETs Progression-Free Survival Benefit* 1.00 Proportion of patients progression free Median PFS Sorafenib = 24 weeks Placebo = 12 weeks Hazard ratio (S/P) = 0.51 Sorafenib Placebo Censored observation Time from randomization (months) *Based on investigator assessment
9 TARGET: Final OS Analysis 16 Months Post-Crossover: Intent-to-Treat 100 OS (% patients) Sorafenib (n=451) = 17.8 months Placebo (n=452) = 15.2 months HR (sorafenib/placebo) = % CI: P=0.146* Time from randomization (months) 561 events *Non-significant; O Brien Fleming threshold for statistical significance α=0.037 Bukowski et al, ASCO 2007
10 TARGET: Pre-planned Secondary Analysis OS Data for Placebo Patients Censored* 100 OS (% patients) Sorafenib (n=451) = 17.8 months Placebo (n=452) = 14.3 months HR (sorafenib/placebo) = % CI: P=0.0287** 0 0 *Censored at 30 June 2005, approx. start of crossover **Statistically significant: O Brien Fleming threshold for statistical significance α= Time from randomization (months) 40 Bukowski et al, ASCO 2007
11 TARGETs: sorafenib has a predictable and manageable side-effect profile Incidence of adverse events* (%) Sorafenib (n=451) Placebo (n=451) Any grade Grades 3 4 Any grade Grades 3 4 Diarrhoea Rash/desquamation <1 Fatigue Hand foot skin reaction Hypertension <1 Dyspnoea Decreased haemoglobin Bone pain Tumour pain *National Cancer Institute-Common Toxicity Criteria (Version 3); adverse events occurring in 2% of patients One patient was not evaluable for safety Escudier B, et al. ECCO 2005, Paris, France
12 Sorafenib induces changes in vascularization 10 Nov 05 9 Dec 05
13 Imaging techniques can show these changes before PR GR after 3W M.Lamuraglia et al. ECCO 2005
14 Changes in tumor vascularization predict OS Lamuraglia et al, Eur J Cancer, 2006
15 But sorafenib is not as active as expected in first line Randomized phase II trial of first-line treatment with sorafenib vs interferon in patients with advanced renal cell carcinoma: final results Cezary Szczylik, Tomasz Demkow, Michael Staehler, Frédéric Rolland, Sylvie Negrier, Thomas E Hutson, Ronald M Bukowski, Urban J Scheuring, Konrad Burk, Bernard Escudier ASCO 2007, abstract 5025
16 Study 11848: Design First-line sorafenib versus IFN: randomized phase II trial ELIGIBILITY CRITERIA Unresectable RCC ± metastases Clear cell histology Measurable disease No prior systemic therapy ECOG Performance Status 0 or 1 Good organ function No brain metastases All MSKCC risk groups Open-label randomization 1:1 Stratification by MSKCC Period 1 Period 2 Sorafenib 400mg bid (n=97) IFN 9 MIU t.i.w. (n=92) PROGRESSION Sorafenib 600mg bid (n=44) Sorafenib 400mg bid (n=51) Primary objective Period 1: PFS sorafenib vs IFN 29 Sept 2006: 121 PFS events Period 2: PFS and clinical benefit 31 Dec 2006 Secondary objective Disease Control Rate (DCR); Quality of Life (QoL); best response rate; duration of response; overall survival (OS)
17 Progression-Free Survival: Period 1 progression-free survival (% patients) Median PFS Sorafenib = 5.7 months IFN = 5.6 months HR (IFN/sorafenib) = 0.88 (95% CI: ) p=0.504 (log-rank test) Time from randomization (months)
18 Results: period 2 IFN sorafenib 400mg bid versus sorafenib 400mg bid 600mg bid ELIGIBILITY CRITERIA Unresectable RCC ± metastases Clear cell histology Measurable disease No prior systemic therapy ECOG Performance Status 0 or 1 Good organ function No brain metastases Open-label randomization 1:1 Stratification by MSKCC Period 1 Sorafenib 400mg orally bid (n=97) IFN 9 MIU t.i.w. (n=92) PROGRESSION Period 2 Sorafenib 600mg bid (SOR ) Sorafenib 400mg bid (IFN SOR400) All MSKCC risk groups Objectives: Is dose escalation useful? Does IFN sorafenib switch mimic TARGET data?
19 Progression-Free Survival: Period 2 SOR N=44 IFN SOR400 N=51 Total with PFS event,* n Median PFS (K M) (95% CI) 4.1 months ( ) 5.5 months ( ) *Investigator assessed; 31 December 2006 cut-off
20 But dose of sorafenib might be too low? A Phase II Trial of Intra-Patient Dose- Escalated-Sorafenib in Patients with Metastatic Renal Cell Cancer R. Amato, P. Harris, M. Dalton, M. Khan, J. Zhai, J. Brady, J. Jac, R. Alter, R. Hauke, S. Srinivas ASCO 2007, abstract 5026
21 Dose Escalated Sorafenib for Renal Cell Carcinoma: Phase 2 Study Treatment regimen: 400 mg bid daily oral therapy day 1-28; 600 mg bid day 29-56; 800 mg bid day 57 throughout Dose modification for grade 3/4 toxicity Monitoring of CBC, chemistry, and amylase/lipase Response assessed by RECIST every 8 weeks Treatment continued unless progression or intolerability
22 Dose Escalated Sorafenib for Renal Cell Carcinoma: Intensity of Therapy At 800 mg dose level 5 patients had dose held between weeks 2 through 4 3 patients were dose reduced Doses were escalated to 1200 mg in 41 of 44 patients Doses were escalated to 1600 mg in 32 of 41 patients SUMMARY 41 patients were able to receive 1200 or 1600 mgs per day of Sorafenib 3 patients were unable to be dose escalated Those with early toxicity have difficulty with dose escalation
23 Dose Escalated Sorafenib for Renal Cell Carcinoma Results: Best Response by RECIST Best Response No. (%) Complete Response 7 16 Partial Response Stable Disease 6 months 9 20 Progression defined as 4 months 11 25
24 And dose of TKIs might be an issue: Probability of PR or CR in mrcc Increased with Mean Daily Sunitinib Exposure Houk et al, ASCO 2007, abstract 5027 Probability of a response 1.0 Mean 95% CI P=0.023 for AUC AUCss sunitinib (ug hr/ml)
25 QUESTIONS 1. Benefit of combination? 2. Benefit of sequential treatment? 3. Rôle of sorafenib?
26 QUESTIONS 1. Benefit of combination? 2. Benefit of sequential treatment? 3. Rôle of sorafenib?
27 Sorafenib plus bevacizumab: phase I/II study design ELIGIBILITY CRITERIA Advanced RCC All histological sub-types ECOG PS 0 1 Prior therapy allowed No VEGF, VEGFR2 or MAP kinase pathways inhibitors Prior nephrectomy not required No CNS disease No active vascular disease (CNS or cardiac) within six months Phase I Week Progression B B B B Sorafenib Re-evaluate Dose escalate until MTD (maximum-tolerated dose) VEGFR = VEGF receptor; MAP = mitogen-activated protein CNS = central nervous system; CR = complete response PR = partial response; SD = stable disease; B = bevacizumab Phase II CR PR SD Progression Continue treatment until tumour progression Off Adapted from: Sosman JA, et al. ASCO 2006; Atlanta, GA, USA
28 Sorafenib plus bevacizumab: phase I/II tumour responses Change in tumour measurements (%) B 3mg/kg + sor 200mg q.d. (n=6) B 5mg/kg + sor 200mg b.i.d. + vitb 6 300mg (n=6) B 5mg/kg + sor 200mg b.i.d. (n=6) B 5mg/kg + sor 400mg b.i.d. + vitb 6 300mg (n=6) Stable disease Response 90 sor = sorafenib q.d. = once daily; vitb 6 = vitamin B 6 Adapted from: Sosman JA, et al. ASCO 2006; Atlanta, GA, USA
29 QUESTIONS 1. Benefit of combination? 2. Benefit of sequential treatment? 3. Rôle of sorafenib?
30 Sequential use of sorafenib and sunitinib: retrospective analysis in 90 patients MP Sablin (1), L Bouaita (1), C Balleyguier (1), J Gautier (2), C Celier (3), S Oudard (4), A Ravaud (3), S Negrier (2), B Escudier (1) (1) Institut Gustave Roussy, Villejuif, France (2) Centre Léon Bérard, Lyon, France (3) Hôpital Saint-André, Bordeaux, France (4) Hôpital Européen Georges Pompidou, Paris, France ASCO 2007
31 Table 4: Efficacy of Su after So So Su PR no. (%) SD no. (%) PD no. (%) NE no. (%) PR no (18) 7 (64) 2 (18) - SD no (13) 24 (53) 11 (25) 4 (9) PD no (20) 3 (30) 4 (40) 1 (10) NE no
32 Table 5: Efficacy of So after Su Su So PR no.(%) SD no.(%) PD no.(%) PR 5 1 (20) 2 (40) 2 (40) SD 12 1 (8) 7 (58) 4 (34) PD (60) 2 (40)
33 Conclusions The sequential administration of sorafenib and sunitinib is beneficial even if this two drugs share the same targets. The use of sorafenib followed by sunitinib seems to be superior with: a better median suvival (not reached vs 70 weeks) better PFS for each arm. the obtention of partial responses after a progression with sorafenib (20%).
34 QUESTIONS 1. Benefit of combination? 2. Benefit of sequential treatment? 3. Role of sorafenib?
35 Sorafenib should be used as first choice therapy in patients who failed cytokines in first line, as a good alternative to interferon after sunitinib activity of sorafenib should continue to be explored: 1.in combination with other agents (bevacizumab, temsirolimus, interferon..) 2.at higher dose, to confirm Amato s data on dose escalation
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
Advanced Renal Cell Carcinoma Individualizing Treatment Selection in the Era of Targeted Therapy Renal Cell Carcinoma In the United States in 28: 54,9 estimated new cases of RCC, estimated deaths Median
PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta S.C. di Oncologia Medica, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia Non-Clear Cell Renal Cell Carcinoma (nccrcc) nccrcc
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
2009 The Authors; Journal compilation 2009 BJU International Mini-review Article MANAGEMENT ALGORITHMS FOR METASTATIC RCC BELLMUNT et al. BJUI BJU INTERNATIONAL Optimal management of metastatic renal cell
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
Targeted Molecular Therapy for Renal Cell Carcinoma: Impact on Existing Treatment Paradigms Wolfram Samlowski, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then
Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
Come valutare la risposta o la progressione nei pazienti in trattamento con terapie biologiche Andrea Busolo U.O. di Radiologia Rocco De Vivo U.O. di Oncologia Medica ULSS 6 - Vicenza Activity and efficacy
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
Perspective Precision oncology: identifying predictive biomarkers for the treatment of metastatic renal cell carcinoma Parth K. Modi 1, Nicholas J. Farber 1, Eric A. Singer 1,2 1 Division of Urology, Rutgers
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
Immunotherapy for Metastatic Renal Cell Carcinoma Timothy M. Kuzel, MD Professor of Medicine and Dermatology Feinberg School of Medicine Northwestern University Chicago, Ilinois ICLIO 1 st Annual National
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
Farmacologia degli inibitori TK e mtor Romano Danesi Professore ordinario di Farmacologia UOC Farmacologia Universitaria Azienda Ospedaliero-Universitaria Pisana Dipartimento di Medicina Interna Università
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
La seconda linea di trattamento: scenario attuale e prospettive future Paolo Andrea Zucali Dipartimento di Oncologia HUMANITAS CANCER CENTER Rozzano - Milano mrcc: second line SECOND-LINE SYSTEMIC THERAPY
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous
Overall Aim and Objectives: Program Synopsis Title: Making Optimal Therapeutic Decisions in Patients with Advanced Renal Cell Carcinoma Clinical Synopsis: New options for targeted treatment of metastatic
mrcc: Tratamiento HOY de segunda línea Pablo Maroto Htal Sant Pau El CCRm precisa de una estrategia de tratamiento Los agentes anti-diana constituyen el tratamiento estandar del CCRm. Pero.. Cómo combinarlos?
Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status
NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Réunion APRAMEN, Paris, 2 février 2013 Philippe RUSZNIEWSKI Pôle des Maladies de
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill firstname.lastname@example.org Primary endpoints in Phase II trials Recently looked at journal articles
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair
1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer
10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
Contemporary Management of Advanced Renal Cell Carcinoma A. Karim Kader MD PhD FRCSC Clinical Fellow in Urologic Oncology The University of Texas M. D. Anderson Cancer Center Epidemiology of RCC ~39,000
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!
Targeted Therapies in Renal Cell Carcinoma mammalian Target of Rapamycin (mtor) Inhibitors Kristen Hehr, Pharm.D. PGY2 Oncology Pharmacy Resident South Texas Veterans Health Care System University of Texas
Clinical Trials for Patients with Malignant Pleural Mesothelioma Lee M. Krug, M.D. Memorial Sloan-Kettering Cancer Center New York, New York Challenges in MPM Clinical Trials Mesothelioma is a rare disease,
Treating Hepatocellular Carcinoma: Medical Oncology Options W. Thomas Purcell, MD, MBA Gastrointestinal Oncology Phase I / Developmental Therapeutics Group Executive Medical Director University of Colorado
The New Kid on the Block for Advanced Renal Cell Carcinoma Wyeth Pharmaceuticals recently launched Torisel (temsirolimus), a targeted, first-in-class mtor inhibitor. This new treatment for metastatic renal
Translocation Renal Cell Carcinomas: Molecular insights and Future Directions Gabriel G. Malouf, MD, PhD Assistant professor Department of medical oncology Pitié-Salpêtrière Hospital, Paris, France Background
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
Cáncer Renal avanzado. Nuevas estrategias para el tratamiento individualizado. Daniel Castellano Oncología Médica.Unidad de Tumores GenitoUrinarios Hospital Universitario 12 de Octubre. I + 12 Research
Technology Assessment Report commissioned by the NHS R&D HTA Programme on behalf of the National Institute for Health and Clinical Excellence Protocol 26 October 2007 PROJECT TITLE Bevacizumab, sorafenib
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
Clinical Trial Results Database Page Sponsor Novartis Generic Drug Name BGT6 Therapeutic Area of Trial Advanced solid malignancies Approved Indication Investigational Study Number CBGT6A0 Title A phase
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
An Open, Multi-Center, Phase II Clinical Trial to Evaluate Efficacy and Safety of Taxol (), UFT, and Leucovorin in Patients with Advanced Gastric Cancer Clinical Study Report 4F, No. 156, Jiankang Rd.,
Corporate Presentation June 2, 2015 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GENITOURINARY RENAL CELL CARCINOMA GU Site Group Renal Cell Carcinoma Date Guideline Created: June 2012 Author: Dr. Charles Catton 1. INTRODUCTION
Latest developments in management Gianfilippo Bertelli Consultant Medical Oncologist Swansea Optimizing management of ovarian cancer in South Wales Diagnosis and referral pathways: Role of GPs, gynaecologists,